Basilea appoints Ronald Scott as CEO to succeed Anthony Man and

Basilea appoints Ronald Scott as CEO to succeed Anthony Man and
expands management team 
BASEL, SWITZERLAND -- (Marketwire) -- 12/10/12 --  Basilea
Pharmaceutica AG / Basilea appoints Ronald Scott as CEO to succeed
Anthony Man and expands management team. 
Processed and transmitted by Thomson Reuters ONE. 
The issuer is solely responsible for the content of this
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has
promoted Ronald Scott, previously Chief Operating
Officer, to Chief
Executive Officer effective January 1, 2013 to succeed Anthony
MD, who has decided for personal reasons to leave the company as of
December 31, 2012. 
"We are very pleased that Ron Scott will assume the role of CEO of
Basilea following the decision of Anthony Man to resign. Ron Scott is
an esteemed business leader in the pharmaceutical industry with a
track record of delivering
results and maintaining organization focus
on business priorities. With several
product candidates including
highly competitive late-stage drugs in our pipeline
and a strong cash
position, Basilea has unique prospects to further create substantial
shareholder value," commented Werner Henrich, chairman of
"Anthony Man is one of the most experienced and respected
drug development executives in industry with an exceptional track
record in bringing drugs through to the market. We sincerely thank
him for his leadership, integrity and
resilience in guiding Basilea
through very rewarding and challenging times and
wish him all the
best for his future endeavors." 
For the last year Ron Scott served as COO responsible for all of
Basilea's operations including technical operations, commercial
activities and finance.
Prior to his position as COO he served as
Basilea's CFO. Ron Scott led the company's equity financings and
significant business transactions. Previously he held senior
management positions in the pharmaceutical industry with over
years of experience and in the financial sector. 
Basilea's Management Committee has been enlarged to include Ms. Heidi
Head of Global Human Resources effective January 1, 2013. The
Management Team's
other members remain Prof. Dr. Achim Kaufhold, Chief
Medical Officer since 2010; Dr. Ingrid Heinze-Krauss, Chief Technical
Officer since 2006; Dr. Laurenz
Kellenberger, Chief Scientific
Officer since 2009; and Joachim Blatter, Chief
Financial Officer
since 2012. 
About Basilea 
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland,
and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully
integrated research and
development operations of its Swiss
subsidiary Basilea Pharmaceutica International Ltd. ("Basilea") the
company focuses on innovative pharmaceutical
products in the
therapeutic areas of bacterial infections, fungal infections and
oncology, targeting the medical challenge of rising resistance and
to current treatment options. 
This communication expressly or implicitly contains certain
forward-looking statements concerning Basilea Pharmaceutica Ltd. and
its business. Such statements involve certain known and unknown
risks, uncertainties and other factors, which could cause the actual
results, financial condition, performance
or achievements of Basilea
Pharmaceutica Ltd. to be materially different from
any future
results, performance or achievements expressed or implied by
forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake
to update any forward-looking statements contained herein as a result
of new information, future
events or otherwise. 
This press release can be downloaded from 
Press release (PDF): 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE 
For further information, please contact: 
Media Relations
Peer Nils Schroder, Ph.D.
Head Public Relations &
Corporate Communications
+41 61 606 1102 
Investor Relations
Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233 |
Press spacebar to pause and continue. Press esc to stop.